BCDA vs. RNXT, INMB, ATNM, KLRS, BLUE, EGRX, RENB, AADI, PRLD, and LIAN
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include RenovoRx (RNXT), INmune Bio (INMB), Actinium Pharmaceuticals (ATNM), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Eagle Pharmaceuticals (EGRX), Renovaro (RENB), Aadi Bioscience (AADI), Prelude Therapeutics (PRLD), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry.
BioCardia vs. Its Competitors
RenovoRx (NASDAQ:RNXT) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.
In the previous week, RenovoRx and RenovoRx both had 2 articles in the media. RenovoRx's average media sentiment score of 0.94 beat BioCardia's score of 0.42 indicating that RenovoRx is being referred to more favorably in the media.
RenovoRx has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
RenovoRx presently has a consensus target price of $7.25, suggesting a potential upside of 457.69%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 1,006.19%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than RenovoRx.
3.1% of RenovoRx shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 9.1% of RenovoRx shares are held by company insiders. Comparatively, 20.0% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
BioCardia has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
RenovoRx's return on equity of -119.58% beat BioCardia's return on equity.
Summary
BioCardia beats RenovoRx on 8 of the 15 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
This page (NASDAQ:BCDA) was last updated on 7/17/2025 by MarketBeat.com Staff
Free BCDA Stock Alerts